Mikhail Fedyanin
Blokhin's Russian Cancer Research Center · FSBI NMITs oncology named after N.N. Blokhin, the Ministry of Health of Russia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mikhail Fedyanin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06978400 · A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal CancerBlokhin's Russian Cancer Research Center · recruiting · Neoplasms · principal investigator
- Ph2NCT06967155 · A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal CancerBlokhin's Russian Cancer Research Center · active not recruiting · Neoplasms · principal investigator
- N/ANCT04905329 · A Multicenter Prospective Post-registration Study of Empegfilgrastim to Evaluate Safety and Efficacy in Special Cancer PopulationsMoscow Clinical Scientific Center · unknown · Solid Tumor, High-Risk Cancer, Breast Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:50 UTC. The ranking covers the 200 most relevant of 10 PubMed records, and a shared surname and initials can bring in a namesake. All 10 on PubMed
- 53 citationsRCR 2.2
- A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.Ann Oncol · 201050 citationsRCR 1.3
- Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).Clin Colorectal Cancer · 201916 citationsRCR 0.5
- First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study.Br J Cancer · 202214 citationsRCR 0.8
- Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.Colorectal Dis · 201313 citationsRCR 0.4
- Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors.J Cancer Res Clin Oncol · 201412 citationsRCR 0.6
- 8 citationsRCR 0.2
- Neoadjuvant Immunotherapy With Prolgolimab in Patients With Locally Advanced Microsatellite Instability/Defective Mismatch Repair Colorectal Cancer.JCO Precis Oncol · 20252 citationsRCR 0.3
- Preoperative chemotherapy in patients with resectable esophageal carcinoma: a single center Phase II study.Jpn J Clin Oncol · 20161 citationsRCR 0.0